Cargando…

Novel Metabolomic Approach for Identifying Pathology-Specific Biomarkers in Rare Diseases: A Case Study in Oculopharyngeal Muscular Dystrophy (OPMD)

The identification of metabolomic biomarkers relies on the analysis of large cohorts of patients compared to healthy controls followed by the validation of markers in an independent sample set. Indeed, circulating biomarkers should be causally linked to pathology to ensure that changes in the marker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harish, Pradeep, Malerba, Alberto, Kroon, Rosemarie H. M. J. M., Shademan, Milad, van Engelan, Baziel, Raz, Vered, Popplewell, Linda, Snowden, Stuart G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302799/ https://www.ncbi.nlm.nih.gov/pubmed/37367926 http://dx.doi.org/10.3390/metabo13060769

Ejemplares similares

Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
por: Harish, Pradeep, et al.
Publicado: (2019)

Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease
por: Harish, Pradeep, et al.
Publicado: (2020)

Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy
por: Raz, Vered, et al.
Publicado: (2020)

Oculopharyngeal Muscular Dystrophy as a Paradigm for Muscle Aging
por: Raz, Yotam, et al.
Publicado: (2014)

P-7 Clinical and electrophysiological feature of 13 Italian patients with oculopharyngeal muscular dystrophy (OPMD)
por: Fiorillo, C., et al.
Publicado: (2011)

Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy
por: Kroon, Rosemarie H.M.J.M., et al.
Publicado: (2020)

Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy
por: Kroon, Rosemarie H.M.J.M., et al.
Publicado: (2021)

Muscle ultrasound is a sensitive biomarker in oculopharyngeal muscular dystrophy
por: Kroon, Rosemarie H. M. J. M., et al.
Publicado: (2022)

Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy
por: Raz, Vered, et al.
Publicado: (2013)

Behavioural Impairment and Frontotemporal Dementia in Oculopharyngeal Muscular Dystrophy
por: Tankink, Maurits, et al.
Publicado: (2022)

Oculopharyngeal muscular dystrophy or oculopharyngeal distal myopathy: case report()
por: Maeda, Marilia Yuri, et al.
Publicado: (2015)

PABPN1 gene therapy for oculopharyngeal muscular dystrophy
por: Malerba, A., et al.
Publicado: (2017)

Recent Progress in Oculopharyngeal Muscular Dystrophy
por: Yamashita, Satoshi
Publicado: (2021)

A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation
por: Nishii, Yo-suke, et al.
Publicado: (2021)

Oculopharyngeal muscular dystrophy as a rare cause of dysphagia
por: Werling, Sarah, et al.
Publicado: (2015)

Dysfunctional transcripts are formed by alternative polyadenylation in OPMD
por: Raz, Vered, et al.
Publicado: (2017)

A decline in PABPN1 induces progressive muscle weakness in Oculopharyngeal muscle dystrophy and in muscle aging
por: Anvar, Seyed Yahya, et al.
Publicado: (2013)

Dysphagia with fatal choking in oculopharyngeal muscular dystrophy: Case report
por: Chen, Andy Wei-Ge, et al.
Publicado: (2018)

The phenotypic and genotypic features of Chinese patients with oculopharyngeal muscular dystrophy
por: Lin, Feng, et al.
Publicado: (2023)

BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
por: Strings-Ufombah, Vanessa, et al.
Publicado: (2021)

Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients
por: Anvar, Seyed Yahya, et al.
Publicado: (2011)

Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy
por: Richard, Pascale, et al.
Publicado: (2017)

RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement
por: Abu-Baker, Aida, et al.
Publicado: (2019)

Oculopharyngeal muscular dystrophy misdiagnosed as myasthenia gravis: Case report and review of literature
por: Aryani, Omid, et al.
Publicado: (2017)

Pharyngeal pathology in a mouse model of oculopharyngeal muscular dystrophy is associated with impaired basal autophagy in myoblasts
por: Zhang, Yu, et al.
Publicado: (2022)

Activation of the ubiquitin-proteasome system contributes to oculopharyngeal muscular dystrophy through muscle atrophy
por: Ribot, Cécile, et al.
Publicado: (2022)

Intranuclear inclusions in muscle biopsy can differentiate oculopharyngodistal myopathy and oculopharyngeal muscular dystrophy
por: Ogasawara, Masashi, et al.
Publicado: (2022)

Oculopharyngeal muscular dystrophy mutations link the RNA‐binding protein HNRNPQ to autophagosome biogenesis
por: Ishtayeh, Hasan, et al.
Publicado: (2023)

Choked: A Case Report of Oculopharyngeal Muscular Dystrophy Mimicking Hypothyroidism From the Philippines
por: Infante, Jerome M, et al.
Publicado: (2023)

Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy
por: Roth, Fanny, et al.
Publicado: (2022)

Oculopharyngeal muscular dystrophy as a rare differential diagnosis for unexplained dysphagia: a case report
por: Bumm, Klaus, et al.
Publicado: (2009)

2396: Utility of the Modified Barium Swallow Impairment Profile as an outcome measure in oculopharyngeal muscular dystrophy
por: Youssof, Sarah, et al.
Publicado: (2018)

Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy
por: Davies, Janet E., et al.
Publicado: (2011)

Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy
por: Barbezier, Nicolas, et al.
Publicado: (2011)

Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/β-catenin pathway
por: Abu-Baker, A, et al.
Publicado: (2013)

An Antibody to Detect Alanine-Expanded PABPN1: A New Tool to Study Oculopharyngeal Muscular Dystrophy
por: Vest, Katherine E., et al.
Publicado: (2015)

Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy
por: Kim, Hong Joo, et al.
Publicado: (2022)

Mitochondrial Dysfunction Reveals the Role of mRNA Poly(A) Tail Regulation in Oculopharyngeal Muscular Dystrophy Pathogenesis
por: Chartier, Aymeric, et al.
Publicado: (2015)

PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy –Consequences in Clinical Diagnosis and Genetic Counselling
por: Richard, Pascale, et al.
Publicado: (2015)

The small compound Icerguastat reduces muscle defects in oculopharyngeal muscular dystrophy through the PERK pathway of the unfolded protein response
por: Naït-Saïdi, Rima, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0t34p5t8h6ekkn1b32tasngdaa